Healthcare Analysts, along with Dr. Asim Shuja, discuss Apraglutide’s Ph.3 STARS data and expectations around uptake in SBS-IF on an Analyst/Industry conference call to be held on March 22 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge
- Ironwood put volume heavy and directionally bearish
- Ironwood price target lowered to $18 from $21 at Craig-Hallum
- Ironwood price target lowered to $14 from $20 at Wells Fargo
- Ironwood reports ‘positive’ results from Phase III trial of apraglutide
